Innovent Biologics to Present Multiple Key Clinical Data at 2020 ASCO Annual Meeting

Suzhou, May 15, 2020 /PRNewswire/ -- Innovent Biologics (HKEX stock code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative medicines for the treatment of major diseases such as cancer, autoimmune disorders, and metabolic diseases, announced today that it will present data on its anti-PD-1 monoclonal antibody Tyvyt®, co-developed with Eli Lilly and Company, in a poster discussion at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO).^®Research data from the ORIENT-2 study on sintilimab injection for the treatment of advanced/metastatic esophageal squamous cell carcinoma after failure of first-line therapy, along with key data from six other clinical studies released via poster presentations and online publications.

Poster Discussion

Title:

Sintilimab in Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma Refractory to Previous Chemotherapy: A Randomized, Open-Label Phase 2 Study (ORIENT-2)

A Randomized, Open-Label, Multicenter Phase II Clinical Trial of Sintilimab for Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy

Abstract Number: 4511

Poster Number: 119

Sub-venue Title:

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Gastrointestinal Tumors—Gastric and Esophageal Cancer, Pancreatic Cancer, and Hepatobiliary Tumors

First Author: Xu Jianming, M.D. (The Fifth Medical Center of Chinese PLA General Hospital)

Poster Presentation

Title:

Phase 1a Dose Escalation of IBI318, a First-in-Class Bispecific Anti-PD-1/PD-L1, in Patients with Advanced Tumors

Phase Ia Clinical Trial of IBI318, a Recombinant Fully Human Anti-Programmed Death Receptor 1 (PD-1) and Anti-Programmed Death Ligand 1 (PD-L1) Bispecific Antibody, for the Treatment of Advanced Malignant Tumors

Abstract Number: 3062

Poster Number: 126

Sub-session Title:

Developmental Therapeutics-Immunotherapy

R&D Stage Therapy—Immunotherapy

First Author: Ruihua Xu, M.D. (Sun Yat-sen University Cancer Center)

Title:

Preliminary Results of Sintilimab Plus Different Dose of IBI305 (anti-VEGF Monoclonal Antibody) in Patients with Advanced Hepatocellular Carcinoma: A Phase 1b Study

Preliminary Phase Ib Clinical Trial Results of Sintilimab Combined with Different Doses of IBI305 (an Anti-VEGF Monoclonal Antibody) in the Treatment of Advanced Hepatocellular Carcinoma

Abstract Number: 3079

Poster Number: 143

Sub-session Title:

Developmental Therapeutics-Immunotherapy

R&D Stage Therapies—Immunotherapy

First Author: Wen Zhang, M.D. (Cancer Hospital, Chinese Academy of Medical Sciences)

Title:

Sintilimab for Relapsed/Refractory Classical Hodgkin's Lymphoma: Long-Term Follow-up on the Multicenter, Single-Arm Phase 2 ORIENT-1 Study

Sintilimab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: Long-term Follow-up Study of the Multicenter, Single-arm Phase II ORIENT-1 Trial

Abstract Number: 8034

Poster Number: 367

Sub-venue Title:

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

First Author: Hang Su, M.D. (Fifth Medical Center of Chinese PLA General Hospital)

Title:

Sintilimab for Relapsed/Refractory (r/r) Extranodal NK/T Cell Lymphoma (ENKTL): Extended Follow-up on the Multicenter, Single-Arm Phase 2 Study (ORIENT-4)

Long-term Follow-up Study of a Multicenter, Single-arm, Phase II Clinical Trial of Sintilimab Monotherapy for Relapsed/Refractory Extranodal NK/T-cell Lymphoma

Abstract No.: 8050

Poster Number: 383

Sub-venue Title:

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

First Author: Li Jianyong, M.D. (Jiangsu Province People's Hospital)

Online Publication

Title:

IBI310 Monotherapy or in Combination with Sintilimab in Patients with Advanced Melanoma: An Open-Label Phase 1a/1b Study

Recombinant Fully Human Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 (CTLA-4) Monoclonal Antibody (Investigational Code: IBI310) as Monotherapy or in Combination with Sintilimab for the Treatment of Advanced Melanoma: An Open-Label Phase Ia/Ib Study

Abstract No.: 302489

First Author: Bin Lian, M.D. (Peking University Cancer Hospital)

Title:

Transarterial Infusion Chemotherapy (TAI) Combined with Sintilimab in Locally Advanced, Potentially Resectable Hepatocellular Carcinoma (HCC)

Hepatic Arterial Infusion Chemotherapy Combined with Sintilimab for the Treatment of Locally Advanced, Potentially Resectable Hepatocellular Carcinoma

Abstract Number: e16593

First Author: Li Xu, MD (Sun Yat-sen University Cancer Center)

About Innovent Bio

“Born from Belief, Realized through Action.” It is Innovent Bio’s vision and goal to develop high-quality biologics that are affordable to the general public. Established in 2011, Innovent Bio is dedicated to the development, manufacturing, and sales of innovative drugs for the treatment of major diseases, including cancer, autoimmune disorders, and metabolic diseases. On October 31, 2018, Innovent Biologics was listed on the Main Board of The Stock Exchange of Hong Kong Limited, with stock code: 01801.

Since its establishment, the company has stood out among numerous biopharmaceutical companies by leveraging innovative achievements and an internationalized operational model. It has built a product pipeline comprising 23 new drug candidates, covering multiple therapeutic areas including oncology, autoimmune diseases, and metabolic disorders. Among these, six candidates were selected for the National “Major New Drug Creation” Special Project, 16 have entered clinical studies, five have advanced to Phase III or pivotal clinical trials, and marketing applications for four monoclonal antibody products have been accepted by the NMPA, with three granted priority review status. One product (Sintilimab Injection, brand name: Tyvyt^®, English Trademark: TYVYT^®) received NMPA approval for market launch, with its first approved indication being relapsed/refractory classical Hodgkin lymphoma, and in November 2019, it became the only PD-1 inhibitor included in the new version of the National Reimbursement Drug List.

Innovent Bio has assembled a high-caliber team for the development and industrialization of biopharmaceuticals, featuring international advanced expertise and numerous returnee experts. The company has established strategic collaborations with global pharmaceutical leaders including Eli Lilly and Company, Adimab, Incyte, and Hanmi Pharmaceutical. Innovent Bio is committed to working collaboratively to elevate the development of China’s biopharmaceutical industry, thereby enhancing drug accessibility for the public and fulfilling people’s aspirations for better health and well-being. For more details, please visit the company website:www.innoventbio.com。